secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001654954-24-001465
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics enrolls first patient in Phase 3 LEVEL study for TNX-103 in PH-HFpEF; topline data expected H2 2025
--------------------------------------------------------------------------------

- First patient enrolled in Phase 3 LEVEL study of oral TNX-103 (levosimendan) for PH-HFpEF; 152-patient trial.
- Over 40 U.S. and Canadian sites agreed to participate, including Mayo, Harvard, Northwestern.
- Topline data forecast for second half of 2025.
- FDA does not require long-term CV outcomes trial, reducing cost and time to registration.
- Patent estate protects TNX-103 through at least 2040.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424001465/0001654954-24-001465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424001465/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-001465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer